Melanoma: Immunotherapy for brain metastases 'doubles survival'



A new study into U.S. cancer data finds that checkpoint blockade immunotherapy doubles median overall survival in melanoma patients with brain metastases.



Source link

Be the first to comment

Leave a Reply

Your email address will not be published.


*